Atopic Dermatitis Clinical Trials

167 recruitingLast updated: June 17, 2026

There are 167 actively recruiting atopic dermatitis clinical trials across 49 countries. Studies span Phase 2, Not Applicable, Phase 1, Phase 3, Phase 4. Top locations include New York, New York, United States, Los Angeles, California, United States, Miami, Florida, United States. Updated daily from ClinicalTrials.gov.


Atopic Dermatitis Trials at a Glance

167 actively recruiting trials for atopic dermatitis are listed on ClinicalTrialsFinder across 6 cities in 49 countries. The largest study group is Phase 2 with 37 trials, with the heaviest enrollment activity in New York, Los Angeles, and Miami. Lead sponsors running atopic dermatitis studies include Pfizer, National Institute of Allergy and Infectious Diseases (NIAID), and Guangdong Hengrui Pharmaceutical Co., Ltd.

Browse atopic dermatitis trials by phase

Treatments under study

About Atopic Dermatitis Clinical Trials

Looking for clinical trials for Atopic Dermatitis? There are currently 143 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Atopic Dermatitis trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Atopic Dermatitis clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 167 trials

Recruiting
Phase 1

Evaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease and/or Atopic Dermatitis

Atopic DermatitisLupusHyper IgE Syndrome From STAT3 Mutation+2 more
National Institute of Allergy and Infectious Diseases (NIAID)20 enrolled1 locationNCT07262983
Recruiting
Phase 1

Phase 1a/1b Study of TRB-061 in Healthy Participants & Patients With Atopic Dermatitis

Moderate-to-severe Atopic Dermatitis
TRex Bio, Inc.115 enrolled15 locationsNCT06934252
Recruiting
Phase 2

Evaluate Efficacy and Safety of Repeat Subcutaneous Doses of FB825 in Adults With Moderate-to-Severe Atopic Dermatitis

Atopic Dermatitis
Oneness Biotech Co., Ltd.114 enrolled16 locationsNCT06397911
Recruiting

Studies of Skin Microbes in Healthy People and in People With Skin Conditions

Atopic DermatitisEczema
National Human Genome Research Institute (NHGRI)530 enrolled1 locationNCT00605878
Recruiting

Identification of Cutaneous and Blood Biomarkers Predictive of Response to Systemic Treatments During Chronic Inflammatory Skin Diseases

lichen planusAtopic DermatitisHidradenitis Suppurativa+9 more
Assistance Publique - Hôpitaux de Paris830 enrolled1 locationNCT06599411
Recruiting

Assessment of cfDNA-STING Axis as a Potential Pathological Marker in Atopic Dermatitis

atopic dermatitis (eczema)
Zhongda Hospital80 enrolled1 locationNCT07573735
Recruiting

Evaluation of a Non-Invasive Device for Early Detection of Atopic Dermatitis Flares

Atopic Dermatitis
Castle Biosciences Incorporated450 enrolled4 locationsNCT07645820
Recruiting

A Study of Stapokibart Injection in Patients With Atopic Dermatitis (AD)

Atopic Dermatitis (AD)
Chengdu Kangnuoxing Biopharma,Inc.1,000 enrolled1 locationNCT07544862
Recruiting
Phase 2

A Long Term Extension Study to Evaluate the Safety and Efficacy of Afimkibart (RO7790121) in Participants With Atopic Dermatitis

Atopic Dermatitis
Hoffmann-La Roche120 enrolled16 locationsNCT07223697
Recruiting
Phase 2

A Long-term Safety and Efficacy Study Evaluating APG777 in Atopic Dermatitis

Atopic Dermatitis
Apogee Therapeutics, Inc.350 enrolled56 locationsNCT07003425
Recruiting
Phase 2

Cardamom and Topical Roseomonas in Atopic Dermatitis

Atopic DermatitisEczema
National Institute of Allergy and Infectious Diseases (NIAID)120 enrolled1 locationNCT06096857
Recruiting
Phase 2

A Dose-ranging Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Galvokimig in Adult Study Participants With Atopic Dermatitis

Atopic Dermatitis
UCB Biopharma SRL160 enrolled64 locationsNCT07277660
Recruiting
Phase 3

A Study to Investigate Safety and Efficacy of Tapinarof Cream, 1% in Participants Ages 3 Months to < 24 Months With Atopic Dermatitis

Atopic Dermatitis
Organon and Co180 enrolled47 locationsNCT07265479
Recruiting
Phase 2

Study of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis

Atopic Dermatitis (AD)
Enveda Therapeutics60 enrolled23 locationsNCT07298395
Recruiting
Phase 4

Molecular Signatures of Cutaneous Dupilumab Response

Atopic Dermatitis
University of California, San Francisco15 enrolled1 locationNCT05858619
Recruiting
Phase 2

A Phase 2b Study of the Effects of Camoteskimab in Adults With Moderate-to-Severe Atopic Dermatitis

DermatitisAtopic DermatitisEczema Atopic Dermatitis+5 more
Apollo Therapeutics Ltd280 enrolled85 locationsNCT07599813
Recruiting

This Study is a Non-interventional Disease Registry of Adolescent and Adult Patients With Atopic Dermatitis Who Initiate or Switch Any Systemic Treatment

Atopic Dermatitis
Sanofi1,000 enrolled56 locationsNCT07290803
Recruiting
Phase 1

Targeted Investigation of Microbiome 2 Treat Atopic Dermatitis (TIME-2)

Atopic Dermatitis
National Institute of Allergy and Infectious Diseases (NIAID)86 enrolled8 locationsNCT06504160
Recruiting

Metabolic Profiling of Immune Responses in Immune-mediated Diseases

Atopic DermatitisPsoriasisPrimary Immunodeficiency+1 more
National Institute of Allergy and Infectious Diseases (NIAID)300 enrolled1 locationNCT04864886
Recruiting
Phase 2

A Study Evaluating BFB759 in Moderate to Severe Atopic Dermatitis

Atopic Dermatitis (AD)
Bluefin Biomedicine, Inc.225 enrolled88 locationsNCT07105488